Moving towards establishing centres of excellence in cardiac amyloidosis: An International Cardio-Oncology Society statement Review
| Authors: | Cheng, R.; Kittleson, M. M.; Wechalekar, A. D.; Alvarez-Cardona, J.; Mitchell, J. D.; Scarlatelli Macedo, A. V.; Dutra, J. P. P.; Campbell, C. M.; Liu, J. E.; Landau, H. J.; Davis, M. K.; Morrissey, S.; Casselli, S.; Lousada, I.; Seabra-Garcez, J. D.; Szor, R. S.; Ganatra, S.; Trachtenberg, B.; Maurer, M. S.; Stockerl-Goldstein, K.; Lenihan, D. |
| Review Title: | Moving towards establishing centres of excellence in cardiac amyloidosis: An International Cardio-Oncology Society statement |
| Abstract: | The prevalence of amyloidosis has been increasing, driven by a combination of improved awareness, evolution of diagnostic pathways, and effective treatment options for both transthyretin and light chain amyloidosis. Due to the complexity of amyloidosis, centralised expert providers with experience in delineating the nuances of confirmatory diagnosis and management may be beneficial. There are many potential benefits of a centre of excellence designation for the treatment of amyloidosis including recognition of institutions that have been leading the way for the optimal treatment of this condition, establishing the expectations for any centre who is engaging in the treatment of amyloidosis and developing cooperative groups to allow more effective research in this disease space. Standardising the expectations and criteria for these centres is essential for ensuring the highest quality of clinical care and community education. In order to define what components are necessary for an effective centre of excellence for the treatment of amyloidosis, we prepared a survey in cooperation with a multidisciplinary panel of amyloidosis experts representing an international consortium. The purpose of this position statement is to identify the essential elements necessary for highly effective clinical care and to develop a general standard with which practices or institutions could be recognised as a centre of excellence. © 2024 BMJ Publishing Group. All rights reserved. |
| Keywords: | treatment response; review; nuclear magnetic resonance imaging; quality of life; amyloidosis; oncology; patient care; societies, medical; total quality management; heart failure; diagnosis; medical society; medical oncology; health care system; cardiomyopathies; bone marrow transplantation; genetic screening; heart amyloidosis; therapy; transthyretin; genetic counseling; cardiomyopathy; cardiology; carpal tunnel syndrome; medication compliance; cardiovascular magnetic resonance; humans; human; emergency physician; cardio-oncology; vertebral canal stenosis; cardiomyopathy, restrictive |
| Journal Title: | Heart |
| Volume: | 110 |
| Issue: | 12 |
| ISSN: | 1355-6037 |
| Publisher: | BMJ Publishing Group Ltd. |
| Date Published: | 2024-06-01 |
| Start Page: | 823 |
| End Page: | 830 |
| Language: | English |
| DOI: | 10.1136/heartjnl-2023-323502 |
| PUBMED: | 38267197 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work